Wuhan Healthgen Biotechnology Corp Class A
SSSE:68876530.43
CNY
-0.79
(-2.53%)
ISIN
CNE100007D17
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Dai Chang Yang
- Full Time Employees
- 253
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Wuhan China
- IPO Date
- Oct 28, 2025
- Website
- oryzogen.com
- Similar Companies
- Business
- Wuhan Healthgen Biotechnology Corp is a China-based biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of plant-derived recombinant proteins and biotherapeutic products. Founded in 2006 and headquartered in Wuhan, China, the company utilizes its proprietary rice endosperm-specific expression platform (OryzExp) to engineer animal-component-free, plant-made pharmaceuticals, industrial enzymes, cell culture media supplements, and research reagents. Wuhan Healthgen Biotechnology operates across four core business segments: Biopharmaceuticals, Cell Culture Ingredients, Medical Device and Diagnostic Materials, and Active Cosmetic Ingredients. Its systematic product and service offerings include clinical-grade plant-derived recombinant human serum albumin (OsrHSA / HY1001) for therapeutic indications including hypoalbuminemia, liver cirrhosis, and hemorrhagic shock; cell culture-grade recombinant human serum albumin used as a serum-free medium supplement, vaccine stabilizer, and cryopreservation agent; recombinant human alpha-1 antitrypsin (OsrAAT / HY1002) for respiratory and inflammatory disorders; recombinant human lactoferrin (OsrLF); recombinant human basic fibroblast growth factor (OsrbFGF); recombinant human epidermal growth factor (OsrEGF); recombinant human fibronectin (OsrFN); recombinant human transferrin; animal-free recombinant trypsin for bioprocessing and cell dissociation; and custom molecular pharming biomanufacturing services. The company distributes its products to pharmaceutical companies, regenerative medicine developers, biotechnology research institutions, and life sciences laboratories across mainland China, North America, Europe, and the Asia-Pacific region. In recent developments, Wuhan Healthgen Biotechnology advanced its listing on the Shanghai Stock Exchange Science and Technology Innovation Board (STAR Market: 688765) to fund clinical pipelines and manufacturing scalability; achieved key clinical milestones for its core injectable recombinant human serum albumin (HY1001) program toward regulatory approval; commissioned its intelligent, large-scale plant molecular pharming industrialization facility in Wuhan; and expanded strategic international distribution and supply agreements to support global commercialization of animal-free raw materials for vaccine production and cell therapy applications.